Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due
to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of …

Objectives : Our aim was to investigate the safety and efficacy of intravenous allogeneic human
mesenchymal stem cells (hMSCs) in patients with myocardial infarction (MI). Background …

Although clinical trials of autologous whole bone marrow for cardiac repair demonstrate
promising results, many practical and mechanistic issues regarding this therapy remain highly …

The underlying mechanism(s) of improved left ventricular function (LV) due to mesenchymal
stem cell (MSC) administration after myocardial infarction (MI) remains highly controversial. …

Background Previous studies of the prognosis of patients with heart failure due to cardiomyopathy
categorized patients according to whether they had ischemic or nonischemic disease. …

Context Mesenchymal stem cells (MSCs) are under evaluation as a therapy for ischemic
cardiomyopathy (ICM). Both autologous and allogeneic MSC therapies are possible; however, …

Inflammatory cardiomyopathy, characterized by inflammatory cell infiltration into the
myocardium and a high risk of deteriorating cardiac function, has a heterogeneous aetiology. …

Background— Ex vivo expansion of resident cardiac stem cells, followed by delivery to the
heart, may favor regeneration and functional improvement. Methods and Results— …

The terms MSC and MSCs have become the preferred acronym to describe a cell and a cell
population of multipotential stem/progenitor cells commonly referred to as mesenchymal …

There is substantial evidence that oxidative stress participates in the pathophysiology of
cardiovascular disease. Biochemical, molecular and pharmacological studies further implicate …